Arcutis Biotherapeutics/$ARQT
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Arcutis Biotherapeutics
Arcutis Biotherapeutics Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for dermatological diseases with high unmet medical needs. Its current portfolio is comprised of differentiated topical and systemic treatments with potential to treat immune-mediated dermatological diseases and conditions. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population. The Company has one reportable segment relating to the development and commercialization of treatments for dermatological diseases.
- Ticker
- $ARQT
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 354
- Headquarters
- Westlake Village, United States
- Website
- www.arcutis.com
ARQT Metrics
BasicAdvanced
$3.3B
123.39
$0.22
1.50
-
Price and volume
Market cap
$3.3B
Beta
1.5
52-week high
$31.77
52-week low
$19.30
Average daily volume
3M
Financial strength
Current ratio
2.917
Quick ratio
2.455
Long term debt to equity
0.486
Total debt to equity
0.517
Interest coverage (TTM)
2.47%
Profitability
EBITDA (TTM)
36.503
Gross margin (TTM)
91.14%
Net profit margin (TTM)
6.15%
Operating margin (TTM)
7.38%
Effective tax rate (TTM)
2.66%
Revenue per employee (TTM)
$1,310,000
Management effectiveness
Return on assets (TTM)
5.09%
Return on equity (TTM)
15.86%
Valuation
Price to earnings (TTM)
123.39
Price to revenue (TTM)
7.387
Price to book
15.13
Price to tangible book (TTM)
16.14
Price to free cash flow (TTM)
87.544
Free cash flow yield (TTM)
1.14%
Free cash flow per share (TTM)
0.304
Growth
Revenue change (TTM)
76.11%
Earnings per share change (TTM)
-129.00%
3-year revenue growth (CAGR)
241.43%
3-year earnings per share growth (CAGR)
-66.03%
What the Analysts think about ARQT
Analyst ratings (Buy, Hold, Sell) for Arcutis Biotherapeutics stock.
Analyst projections of the future price of Arcutis Biotherapeutics stock.
Bulls say / Bears say
ZORYVE sales rose 59% year on year to $129.9 million in the second quarter, prompting Arcutis to raise its 2026 sales guidance to $525 million–$540 million. That points to strong demand and continued commercial momentum. (Arcutis Biotherapeutics)
Arcutis recorded $15.0 million of net income and $12.6 million of operating cash flow in the second quarter. Positive cash generation could help fund growth and product development without relying as heavily on new financing. (Arcutis Biotherapeutics)
The FDA expanded ZORYVE cream’s psoriasis approval to children as young as two, while it has accepted a separate application for use in infants with atopic dermatitis. These age expansions could broaden the addressable patient base if uptake follows. (Arcutis Biotherapeutics, Arcutis Biotherapeutics)
Arcutis relies heavily on ZORYVE in a competitive dermatology market, leaving its results exposed if prescriptions weaken or rivals gain ground. The company does not yet have another commercial franchise at comparable scale to cushion a setback. (The Motley Fool)
Arcutis identifies its ability to defend its intellectual property as a business risk. If its patent protection proves inadequate, generic competition could threaten sales of its key franchise. (Arcutis Biotherapeutics, U.S. Securities and Exchange Commission)
Profitability is not yet proven to be durable: first-half 2026 net income was only $3.7 million, and Arcutis says it may continue to incur operating losses. Continued commercial spending could make earnings sensitive to any slowdown in sales growth. (U.S. Securities and Exchange Commission, Arcutis Biotherapeutics)
Data summarised monthly by Lightyear AI. Last updated on 9 Oct 2026.
ARQT Financial Performance
Revenues and expenses
ARQT Earnings Performance
Company profitability
Upcoming events
No upcoming events
ARQT News
AllArticlesVideos
Funds containing ARQT
AllUSDGBPEUR
Fund name | Fund size | $ARQT weighting |
|---|---|---|
iShares Nasdaq US Biotechnology$BTEC | $1.2B | 0.22% |
iShares Nasdaq US Biotechnology£BTEK | £865M | 0.22% |
iShares S&P SmallCap 600$IDP6 | $3.2B | 0.18% |
iShares S&P Small Cap 600£ISP6 | £2.4B | 0.18% |
SPDR Russell 2000 US Small Cap€R2US | €4.8B | 0.10% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.